Bioxyne Limited (BXN) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$214M
Fair value as of: Jul 11, 2026
From 24 valuation models · updated today
Fair value updated Jul 11, 2026 — revised from A$0.0400 to A$0.4100 (+925.0%) since Jun 26, 2026. Share price +4.7% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3300 – A$1.05 · fair‑value band A$0.2800 – A$0.5100 · the A$0.9000 price screens above the A$0.4100 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bioxyne Limited (BXN) currently trades at A$0.9000, while our model-based Fair Value estimate is A$0.4100 — implying the stock looks roughly 54.4% overvalued today. We read business quality at 70/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Bioxyne Limited generated revenue of A$48.0M at a net margin of 18.7%. Revenue grew 149.6% year over year. It earns a return on equity of 66.1%. The balance sheet holds a net cash position of A$6.1M. Fundamentals as of Jul 11, 2026
Our scenario range runs from A$0.2800 (bear case) to A$0.5100 (bull case); at A$0.9000, the current price sits above that range. For context, the median of 10 Consumer Defensive peers we cover trades at -27% fair-value upside — at -54%, BXN screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioxyne Limited reported revenue of A$30.4M in FY2025 versus A$2.1M in FY2021, a compound +94.9%/yr. Reported net income was A$4.9M in FY2025.
Is BXN fairly valued? → Check now
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $97.58 | $65.41 | -33% |
| Nestlé India Limited NESTLEIND | ₹1,438 | ₹362.37 | -75% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 83.34 MXN | +46% |
| Uni-President Enterprises Corp 1216 | 75.60 TWD | 55.53 TWD | -27% |
| Britannia Industries Limited BRITANNIA | ₹5,218 | ₹3,567 | -32% |
| Tata Consumer Products Limited TATACONSUM | ₹1,131 | ₹339.05 | -70% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 6,600 IDR | 14,500 IDR | +120% |
| Samyang Foods Co 003230 | 1,000,000 KRW | 1,066,643 KRW | +7% |
| PT Indofood Sukses Makmur Tbk INDF | 6,250 IDR | 22,853 IDR | +266% |
| Patanjali Foods Limited PATANJALI | ₹420.45 | ₹294.68 | -30% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Bioxyne Limited (BXN) undervalued?
What is the fair value of BXN?
What is the quality score of BXN?
What is the revenue of Bioxyne Limited (BXN)?
What is the net profit margin of BXN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Bioxyne Limited analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.